Elephas Biosciences and Tes Pharma, an Italy-based biopharmaceutical company focused on developing therapeutics for unmet medical needs, announced today that they are collaborating to advance translational research for lung therapy.

According to a release, the firms will evaluate TES-4207, a first-in-class investigational therapy targeting NR2F6 for treatment of non-small cell lung cancer (NSCLC).

“We are pleased to collaborate with Tes Pharma and apply our elive platform to the development of TES-4207,” Elephas Vice President of Scientific Affairs Erika von Euw, PhD, said in a statement. “Evaluating TES-4207 directly in live tumor tissue, both as a monotherapy and in combination with PD-1 blockade, allows us to capture tissue-specific functional responses while preserving the complexity of the tumor microenvironment. These insights can help inform clinical development and support a more precise approach to identifying groups most likely to benefit.”

As part of the agreement, Elephas’ elive platform will characterize functional response to TES-4207 in live human NSCLC tumor tissue, as a monotherapy and in combination therapy.